Alpha 2.0
Login Register
» Authors » Paul D Richards

Paul D Richards

Explore the profile of Paul D Richards including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 112
Followers 0
Related Specialty
Oncology
Top 10 Co-Authors
Carrie L Dul
Mary K Murray
Laura A Lee
James V Pellicane
Rakhshanda Layeequr Rahman
William Audeh
Devchand Paul
Andrea R Menicucci
Andrew Y Ashikari
Shiyu Wang
Published In
Clin Breast Cancer
Ann Surg Oncol
Breast Cancer Res Treat
JCO Precis Oncol
Leuk Res
Affiliations
Soon will be listed here.
Recent Articles
1.
Genomic Classification of HER2-Positive Patients With 80-Gene and 70-Gene Signatures Identifies Diversity in Clinical Outcomes With HER2-Targeted Neoadjuvant Therapy
Whitworth P, Beitsch P, Murray M, Richards P, Mislowsky A, Dul C, et al.
JCO Precis Oncol . 2022 Sep; 6:e2200197. PMID: 36108259
Purpose: The prospective Neoadjuvant Breast Registry Symphony Trial compared the 80-gene molecular subtyping signature with clinical assessment by immunohistochemistry and/or fluorescence in situ hybridization in predicting pathologic complete response (pCR)...
2.
Age-Independent Preoperative Chemosensitivity and 5-Year Outcome Determined by Combined 70- and 80-Gene Signature in a Prospective Trial in Early-Stage Breast Cancer
Whitworth P, Beitsch P, Pellicane J, Baron P, Lee L, Dul C, et al.
Ann Surg Oncol . 2022 Apr; PMID: 35378634
Background: The Neoadjuvant Breast Symphony Trial (NBRST) demonstrated the 70-gene risk of distant recurrence signature, MammaPrint, and the 80-gene molecular subtyping signature, BluePrint, precisely determined preoperative pathological complete response (pCR)...
3.
Pertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+ Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)
Beitsch P, Whitworth P, Baron P, Rotkis M, Mislowsky A, Richards P, et al.
Ann Surg Oncol . 2017 Apr; 24(9):2539-2546. PMID: 28447218
Background: Pertuzumab became a standard part of neoadjuvant therapy for human epidermal growth factor receptor 2-positive (HER2+) breast cancers approximately halfway through Neoadjuvant Breast Registry Symphony Trial (NBRST) enrollment, providing...
4.
Relation between chelation and clinical outcomes in lower-risk patients with myelodysplastic syndromes: Registry analysis at 5 years
Lyons R, Marek B, Paley C, Esposito J, McNamara K, Richards P, et al.
Leuk Res . 2017 Mar; 56:88-95. PMID: 28242540
Prospective data are needed to ascertain the impact of iron chelation therapy in patients with myelodysplastic syndromes. The present 5-year prospective registry analysis was conducted to compare clinical outcomes between...
5.
Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study
Yardley D, Reeves J, Dees E, Osborne C, Paul D, Ademuyiwa F, et al.
Clin Breast Cancer . 2016 Aug; 16(6):471-479.e1. PMID: 27569274
Background: Use of antiangiogenic agents in treatment of metastatic breast cancer (MBC) remains controversial. We evaluated the efficacy and safety of ramucirumab and eribulin versus eribulin alone as third- to...
6.
A phase II trial of trabectedin in triple-negative and HER2-overexpressing metastatic breast cancer
Blum J, Goncalves A, Efrat N, Debled M, Conte P, Richards P, et al.
Breast Cancer Res Treat . 2016 Jan; 155(2):295-302. PMID: 26749361
Trabectedin is an alkylating agent that binds to the minor groove of DNA. Early studies with trabectedin suggested efficacy in triple-negative and HER2-overexpressing metastatic breast cancer (MBC). The efficacy and...
7.
Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial
Robert N, Saleh M, Paul D, Generali D, Gressot L, Copur M, et al.
Clin Breast Cancer . 2011 May; 11(2):82-92. PMID: 21569994
Introduction: A multicenter, open-label phase III study was conducted to test whether sunitinib plus paclitaxel prolongs progression-free survival (PFS) compared with bevacizumab plus paclitaxel as first-line treatment for patients with...